Bionitlabs

BionIT Labs operates at the intersection of upper-limb prosthetics, medical robotics and dexterous manipulation for physical AI. Its core differentiation is Adam’s Hand’s fully adaptive grasping architecture: a single motor drives four long fingers while the thumb is separately actuated, allowing the fingers to conform to objects without relying on preset grip patterns. The company states that more than 200 hands are in daily use across ten countries, and its products are CE marked under MDR, FDA registered and supported by ISO 9001 and ISO 13485 quality systems. That gives BionIT Labs a regulated-device foundation that many robotics entrants lack. The company is not directly comparable to a pure software robotics provider; its nearer competitive set includes established prosthetics manufacturers and emerging bionic-hand developers, although no specific peer companies are identified in the available comparable-company records. Its robotics expansion brings it into competition for dexterous end-effectors with humanoid-robot hardware specialists. The principal strategic question is whether clinical validation, user-generated manipulation data and a lighter mechanical design can translate into reliable industrial deployments.

BionIT Labs has followed a staged capital and product-development trajectory since its 2018 founding. Early financing included a February 2019 pre-seed round, an August 2019 grant and equity crowdfunding, followed by a further pre-seed round announced on Feb 2, 2021. The company then raised approximately $4.02 million in a Nov 10, 2021 seed round led by CDP Venture Capital and Equiter. Its largest disclosed financing came on Jul 3, 2024, when it raised approximately $5.94 million, bringing structured cumulative funding to about $10.86 million. Product development progressed from Adam’s Hand and its clinical support stack—MyoLogic, MyoLogic Pro, PRISM and Adam’s Skin—to a robotics-oriented platform. The September 2025 Chattanooga headquarters represents an operational inflection point, adding a U.S. base and an active hiring effort. The January 2026 launch for humanoids and service robots, followed by CES 2026 demonstrations, marks the clearest move from prosthetics into physical AI. The company reports 73 employees and more than 200 hands in daily use across ten countries, but public information does not establish revenue, deployment volume in robotics or the pace of U.S. commercialization.